In UK men aged 50–69 years, using reference ranges for “normal” PSA change with age or the age group-specific thresholds suggested by the NICE guidelines resulted in fewer unnecessary biopsies but at the cost of more missed prostate cancers. Here, KLK3 is linked to prostate cancer.